Filing Details

Accession Number:
0000899243-20-021031
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-08-03 19:10:53
Reporting Period:
2020-07-30
Accepted Time:
2020-08-03 19:10:53
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1340652 Chemocentryx Inc. CCXI Pharmaceutical Preparations (2834) 943254365
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1416422 Ltd. Pharma Vifor Rechenstrasse 37
Ch-9014 St. Gallen V8
No No Yes No
1675217 Ltd (International) Vifor Rechenstrasse 37
Ch-9014 St. Gallen V8
No No Yes No
1757924 Ltd. Pharma Renal Care Medical Fresenius Vifor Rechenstrasse 37
Ch-9014 St. Gallen V8
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, Par Value $0.001 Per Share Disposition 2020-07-30 1,156 $53.37 9,330,670 No 4 S Indirect See Footnotes
Common Stock, Par Value $0.001 Per Share Disposition 2020-07-30 24,458 $54.43 9,306,212 No 4 S Indirect See Footnotes
Common Stock, Par Value $0.001 Per Share Disposition 2020-07-30 22,467 $54.85 9,283,745 No 4 S Indirect See Footnotes
Common Stock, Par Value $0.001 Per Share Disposition 2020-07-31 10,009 $51.74 9,273,736 No 4 S Indirect See Footnotes
Common Stock, Par Value $0.001 Per Share Disposition 2020-07-31 29,699 $52.57 9,244,037 No 4 S Indirect See Footnotes
Common Stock, Par Value $0.001 Per Share Disposition 2020-07-31 694 $54.33 9,243,343 No 4 S Indirect See Footnotes
Common Stock, Par Value $0.001 Per Share Disposition 2020-08-03 785 $52.92 9,242,558 No 4 S Indirect See Footnotes
Common Stock, Par Value $0.001 Per Share Disposition 2020-08-03 31,823 $53.62 9,210,735 No 4 S Indirect See Footnotes
Common Stock, Par Value $0.001 Per Share Disposition 2020-08-03 16,650 $54.58 9,194,085 No 4 S Indirect See Footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
Footnotes
  1. In addition to Vifor (International) Ltd., an entity formed under the laws of Switzerland ("Vifor"), and Vifor Fresenius Medical Care Renal Pharma Ltd., an entity formed under the laws of Switzerland ("VFMCRP"), this Form 4 is being filed by Vifor Pharma Ltd., an entity formed under the laws of Switzerland ("Vifor Pharma" and, together with Vifor and VFMCRP, the "Reporting Persons"). The business addresses for each of the Reporting Persons are listed above. Each of the Reporting Persons may be deemed to have a pecuniary interest in securities reported by it on this Form 4 (the "Subject Securities").
  2. Beneficial ownership of the common stock referred to herein is being reported solely because (i) Vifor Pharma may be deemed to beneficially own 5,860,752 shares of Common Stock of ChemoCentryx, Inc. as a result of Vifor Pharma's indirect ownership of 100% of the equity interests of Vifor, and (ii) Vifor Pharma may be deemed to beneficially own 3,333,333 shares of Common Stock of ChemoCentryx, Inc. as a result of Vifor Pharma's indirect ownership of 55% of the equity interests of VFMCRP.
  3. Each of the Reporting Persons disclaims any beneficial ownership of any of the Subject Securities, except to the extent of any pecuniary interest therein.
  4. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Vifor on June 26, 2020.
  5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.63 to $53.60, inclusive. Vifor undertakes to provide ChemoCentryx, Inc., any security holder of ChemoCentryx, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (5), (6), (7), (8), (9), (10), (11), (12) and (13) to this Form 4.
  6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.64 to $54.63, inclusive.
  7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.64 to $55.34, inclusive.
  8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.15 to $52.14, inclusive.
  9. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.17 to $53.02, inclusive.
  10. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.19 to $55.00, inclusive.
  11. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.27 to $53.24, inclusive.
  12. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.28 to $54.18, inclusive.
  13. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.32 to $54.81, inclusive.